Everything below concerns NR1D1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
After these events, in 1989 Assembly of Socialist Republic of Serbia voted for constitution amendments that revoked high autonomy for provinces of Vojvodina and Kosovo. After Slovenian authorities forbid a group of Serbs supporting his politics to gather in Ljubljana, Milosević started a trade war with Socialist Republic of Slovenia in late 1989. This Serbian–Slovenian conflict culminated in January 1990 on 14th Congress of the League of Communists of Yugoslavia when Slovenians left the meeting followed by Croatian delegates. After 1990, the state was known simply as Republic of Serbia (Serbo-Croatian: Република Србија / Republika Srbija), and in December of the same year, Slobodan Milošević was elected as first President of the Republic. In 1992, when the Federal Republic of Yugoslavia was formed, Serbia became one of its two constituent republics. In 2003, this state union was re-formed into Serbia and Montenegro, and in 2006, Serbia became an independent republic after Montenegro separated.
β-carotene can be extracted from fungus Blakeslea trispora, marine algae Dunaliella salina or genetically modified yeast Saccharomyces cerevisiae, starting with xylose as a substrate. Chemical synthesis uses either a method developed by BASF or a Grignard reaction utilized by Hoffman-La Roche. The world market for synthetic retinol is primarily for animal feed, leaving approximately 13% for a combination of food, prescription medication and dietary supplement use. Industrial methods for the production of retinol rely on chemical synthesis. The first industrialized synthesis of retinol was achieved by the company Hoffmann-La Roche in 1947. In the following decades, eight other companies developed their own processes. β-ionone, synthesized from acetone, is the essential starting point for all industrial syntheses. Each process involves elongating the unsaturated carbon chain. Pure retinol is extremely sensitive to oxidization and is prepared and transported at low temperatures and oxygen-free atmospheres. When prepared as a dietary supplement or food additive, retinol is stabilized as the ester derivatives retinyl acetate or retinyl palmitate. Prior to 1999, three companies, Roche, BASF and Rhone-Poulenc controlled 96% of global vitamin A sales. In 2001, the European Commission imposed total fines of 855.22 million euros on these and five other companies for their participation in eight distinct market-sharing and price-fixing cartels that dated back to 1989. Roche sold its vitamin division to DSM in 2003. DSM and BASF have the major share of industrial production.
==== Oral appliances ==== An oral appliance, often referred to as a mandibular advancement splint, is a custom-made mouthpiece that shifts the lower jaw forward and opens the bite slightly, opening up the airway. These devices can be fabricated by a general dentist. Oral appliance therapy is usually successful in patients with mild to moderate obstructive sleep apnea. While CPAP is more effective for sleep apnea than oral appliances, oral appliances improve sleepiness and quality of life and are often better tolerated than CPAP. A novel oral device, the C.A.R.E. device (DNA, mRNA and mmRNA), has a dual action of both holding the lower jaw (mandible) forward to open the airway while sleeping and developing the volume of the upper jaw bone (maxilla) improving nasal volume. Many dental appliances can expand the maxilla and increase the nasal airway volume as measured by CBCT and acoustic rhinometry but the novel C.A.R.E. device (DNA, mRNA and mmRNA) has a protocol for wear time and adjustment that is different than these devices. This has resulted in the safe and effective resolution of sleep apnea in children and adults. The CARE device (DNA, mRNA and mmRNA) and protocol was FDA cleared for snoring and for obstructive sleep apnea in 2023. Larger studies are needed. Cross-functional team research is needed to specifically determine the impact of oral devices and their materials that i.e. might stimulate osteogenesis potentially changing the size and shape of a bone (the maxilla).
Sources: en.wikipedia.org
International Union of Biochemistry and Molecular Biology (IUBMB) An international non-governmental organization devoted to promoting scientific research and education in the disciplines of biochemistry and molecular biology, primarily by standardizing biochemical nomenclature, developing and publishing laboratory methods, and awarding grants and fellowships to students and researchers.
=== Healthcare === The Ajinomoto Group's healthcare business is based on using the fermentation technology of amino acids. In 1956, Ajinomoto began producing the world's first amino acid infusion, enteral nutrition products, and crystalline amino acids that could be used as raw materials in pharmaceutical products. Currently, Ajinomoto manufactures around twenty kinds of amino acids at various factories overseas, including plants in Japan, the United States, Europe, and India. In 1995, Ajinomoto began selling an amino acid supplement called Amino Vital for professional sports athletes. In 2011, Ajinomoto began offering an "Amino Index" health checkup, which statistically analyzes the difference in amino acid concentrations between healthy individuals and adults suffering from cancer and other serious diseases to aid the early detection of cancer and other diseases. In addition to glutamates as a seasoning, the company also produces other amino acids such as L-Leucine, L-Tyrosine, Glycine, and L-Phenylalanine, which it markets as dietary supplements under the brand name AjiPure.
== History == Basilea Pharmaceutica was founded in 2000 as a corporate spin-off of the pharmaceutical company Roche. In 2002, Chinese subsidiary Basilea Pharmaceutica China Ltd. (BPC) was founded and was located in the Haimen Economic and Technological Development Zone in the city of Nantong in the Chinese province of Jiangsu, north of Shanghai. With the listing on the Swiss stock exchange in March 2004 at a price of CHF 98 per share, Basilea realised gross proceeds of more than CHF 200 million. In 2012, Basilea sold the worldwide rights to Toctino, a dermatology drug developed by Basilea that was approved and marketed in various European countries in 2008, to Stiefel Labs, a subsidiary of the British pharmaceutical company GlaxoSmithKline, for CHF 216 million. At the beginning of 2013, Basilea received orphan drug status in the USA for the antifungal drug Isavuconazole for the treatment of invasive fungal infections, which at the time, analysts estimated to be worth up to CHF 150 million per year. Isavuconazole was developed in phase III in conjunction with pharmaceutical company Astellas Pharma. In March 2015, Isavuconazole was approved in the US, followed by the entire EU in October of the same year. In the following years, the drug was also approved in Japan, several Eurasian countries, Australia and China.
==== Positive psychology interventions (PPI) in patients ==== A strengths-based approach to personal positive change aims to have clinical psychology place an equal weight on both positive and negative functioning when attempting to understand and treat distress. This rationale is based on empirical findings. Because positive characteristics interact with negative life events to predict disorder the exclusive study of negative life events could produce misleading results. Positive activity interventions, or PAIs, are brief self-administered exercises that promote positive feelings, thoughts, and behaviors. Two widely used PAIs are "Three Good Things" and "Best Future Self." "Three Good Things" requires a patient to daily document, for a week, three events that went well during the day, and the respective cause, or causes (this exercise can be modified with counterfactual thinking, that is, adding the imagination of things had them been worse). "Best Future Self" has a patient "think about their life in the future, and imagine that everything has gone as well as it possibly could. They have worked hard and succeeded at accomplishing all of their life goals. Think of this as the realization of all of their life dreams." The patient is then asked to write down what they imagined. These positive interventions have been shown to decrease depression, and interventions focusing on strengths and positive emotions can, in fact, be as effective in treating disorder as other more commonly used approaches such as cognitive behavioral therapy.
Sources: en.wikipedia.org
The PC version received "mixed or average reviews" according to the review aggregation website Metacritic. In a review for IGN, critic Tal Blevins noted that Blue Shift's gameplay "is pretty much what we've come to expect out of Half-Life" by blending action and puzzle solving, stating that the latter "were all logical and well done, although some of the jumping puzzles were frustrating". Though IGN praised the game for maintaining the "epic" feel of the original, Blevins was critical of the relatively short length of the game. GameSpot reviewer Greg Kasavin agreed with many of IGN's criticisms, stating that "it's not that the game is easy so much that it's extremely short" and that Blue Shift "doesn't amount to much on its own terms". In addition, Kasavin described the graphical enhancements brought about by the High Definition pack as "helpful", but noted that "they still don't make Half-Life look like a new game—nor are many of the changes themselves very noticeable". Other reviews echoed complaints about the similarity of Blue Shift to previous games. GameSpy reviewer Jamie Madigan stated that "what really pulls the game down is the 'more of the same' factor". Although writing that the game "feels like just a few more levels for the original game", he noted that this is what Blue Shift was designed to be, given its origins as an add-on for a Dreamcast version of Half-Life. Madigan described the single-player campaign as "decent" and commented that the new graphics made the game "worthy of consideration".
Autocrine signaling involves a cell secreting a hormone or chemical messenger (called the autocrine agent) that binds to autocrine receptors on that same cell, leading to changes in the cell itself. This can be contrasted with paracrine signaling, intracrine signaling, or classical endocrine signaling.
=== Cuban oil reserves === On 25 April 2026, Miguel Díaz-Canel celebrated this week as a historic milestone the fact that Cuban national crude can be refined, when in reality the Cabaiguán refinery has been processing that same oil since 2010, as acknowledged by the deputy director of CUPET during the April session of the National Council of Innovation (CNI). The announcement from the Cuban government revolves around a thermal conversion technology developed by the Oil Research Center (Ceinpet), affiliated with the Union Cuba Petróleo (CUPET), to process the heavy crude from the northern oil belt, characterized by its high density, viscosity, and sulfur content.
== Epidemiology == A large study found a rate of 29% over a woman's lifetime. Other studies indicate a recurrence rate as low as 3%. In the US, greater than 200,000 surgeries are performed each year for pelvic organ prolapse and 81% of these are to correct cystocele. Cystocele occurs most frequently compared to the prolapse of other pelvic organs and structure. Cystocele is found to be three times as common as vaginal vault prolapse and twice as often as posterior vaginal wall defects. The incidence of cystocele is around 9 per 100 women-years. The highest incidence of symptoms occurs between the ages of 70 and 79 years. Based on population growth statistics, the number of women with prolapse will increase by a minimum of 46% by the year 2050 in the US. Surgery to correct prolapse after hysterectomy is 3.6 per 1,000 women-years.
== Mechanism of action == Ptaquiloside has unstable chemical structure and readily undergoes glucose liberation. The resulting ptaquilodienone is the active form of ptaquiloside and accounts for the observed biological effects. The cyclopropyl group in the dienone is highly reactive as an electrophile, not only because it is conjugated with the keto group, but because it also constitutes a cyclopropyl carbinol system, from which the facile formation of the stable non-classical cation is well-known.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.